COMP <GO>
IRMD vs IART // ENTERPRISE SCALE & MARKET CAP
iRadimed Corporation (NASDAQ) VS. Integra LifeSciences Holdings Corporation (NASDAQ) • 15-METRIC TALLY: IRMD 9
— IART 1
▲ ENTERPRISE SCALE & MARKET CAP LEADER: IRMD
LAST: $85.74 (+2.16%) • MKT CAP: $1.10B
market-cap
$1.10B
LAST: $12.83 (+4.82%) • MKT CAP: $998.2M
market-cap
$998.2M
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (IRMD VS. IART)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | IRMD | IART | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 76.70% | 50.90% | +25.80 | IRMD | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 37.70% | -35.00% | +72.70 | IRMD | /roic <GO> |
| EV/EBITDA & P/E Valuation | 31.9x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 1.57% | -3.11% | +4.68 | IRMD | /fcf-yield <GO> |
| Operating Margin | 31.20% | -30.20% | +61.40 | IRMD | /operating-margins <GO> |
| Net Profit Margin | 26.80% | -31.60% | +58.40 | IRMD | /net-margins <GO> |
| Revenue Growth (YoY) | 14.40% | 1.50% | +12.90 | IRMD | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 1.37% | 0.00% | +1.37 | IRMD | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 0.64 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 4/9 | +4.00 | IRMD | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 25.6 | 42.8 | -17.18 | IART | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 41.0x | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap ACTIVE | $1.10B | $998.2M | $98.2M | IRMD | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | IRMD REV | IART REV | IRMD GROSS % | IART GROSS % | IRMD FCF | IART FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $83.8M | $1.64B | 76.7% | 50.9% | $17.2M | -$31.1M |
| FY 2024 | $73.2M | $1.61B | 76.9% | 54.8% | $17.6M | $25.0M |
| FY 2023 | $65.6M | $1.54B | — | — | $13.5M | $140.0M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
IRMD // BETA —
IART // BETA —